The Critical Role of Pharmacists in the Clinical Delivery of Pharmacogenetics in the U.S
Since the rebirth of pharmacogenomics (PGx) in the 1990s and 2000s, with new discoveries of genetic variation underlying adverse drug response and new analytical technologies such as sequencing and microarrays, there has been much interest in the clinical application of PGx testing. The early involvement of pharmacists in clinical studies and the establishment of organizations to support the dissemination of information about PGx variants have naturally resulted in leaders in clinical implementation. This paper presents an overview of the evolving role of pharmacists, and discusses potential challenges and future paths, primarily focused in the U.S. Pharmacists have positioned themselves as leaders in clinical PGx testing, and will prepare the next generation to utilize PGx testing in their scope of practice.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Pharmacy (Basel, Switzerland) - 11(2023), 5 vom: 10. Sept. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Haga, Susanne B [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Barriers |
|---|
| Anmerkungen: |
Date Revised 24.09.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/pharmacy11050144 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362335141 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362335141 | ||
| 003 | DE-627 | ||
| 005 | 20231226091025.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/pharmacy11050144 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1207.xml |
| 035 | |a (DE-627)NLM362335141 | ||
| 035 | |a (NLM)37736916 | ||
| 035 | |a (PII)144 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Haga, Susanne B |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Critical Role of Pharmacists in the Clinical Delivery of Pharmacogenetics in the U.S |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 24.09.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Since the rebirth of pharmacogenomics (PGx) in the 1990s and 2000s, with new discoveries of genetic variation underlying adverse drug response and new analytical technologies such as sequencing and microarrays, there has been much interest in the clinical application of PGx testing. The early involvement of pharmacists in clinical studies and the establishment of organizations to support the dissemination of information about PGx variants have naturally resulted in leaders in clinical implementation. This paper presents an overview of the evolving role of pharmacists, and discusses potential challenges and future paths, primarily focused in the U.S. Pharmacists have positioned themselves as leaders in clinical PGx testing, and will prepare the next generation to utilize PGx testing in their scope of practice | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a barriers | |
| 650 | 4 | |a education | |
| 650 | 4 | |a pharmacist | |
| 650 | 4 | |a pharmacogenetic testing | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacy (Basel, Switzerland) |d 2015 |g 11(2023), 5 vom: 10. Sept. |w (DE-627)NLM263438279 |x 2226-4787 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2023 |g number:5 |g day:10 |g month:09 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/pharmacy11050144 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2023 |e 5 |b 10 |c 09 | ||